POTENTIAL BENEFITS OF RSV VACCINATION IN COLOMBIAN ADULTS AGED 60 AND OVER: A COST-UTILITY ANALYSIS
Author(s)
Jaime Ordoñez, MEd, PhD;
TrueConsulting, Medellín, Colombia
TrueConsulting, Medellín, Colombia
OBJECTIVES: To evaluate the cost-utility of the RSVpreF vaccine for Colombian adults aged 60 years and older, with a lifetime horizon from the public health system perspective.
METHODS: A decision-tree model simulated a fixed cohort of Colombian adults aged ≥60 over their remaining lifetime. The intervention was a one-time administration of a recombinant RSV prefusion F protein vaccine, compared with no vaccination. Epidemiological inputs were derived from Colombian and Latin American studies, in which administrative incidence data were used. General population mortality was obtained from the official life tables published by the National Financial Supervisory Authority. Costs were derived from expert consensus, official national reimbursement data, and PAHO records. Vaccine efficacy was obtained from the RENOIR randomized controlled trial, whereas vaccine effectiveness for hospitalization was from the Kaiser Permanente Southern California (KPSC) Study. A vaccine uptake of 17.8% is set, based on Influenza uptake for Colombian adults in 2018. A 5% annual discount rate was applied to both costs and outcomes. Deterministic and probabilistic sensitivity analyses were implemented to explore uncertainty. The willingness-to-pay (WTP) threshold was USD 8,266 per QALY gained
RESULTS: Vaccination averted 2,716 RSV-related hospitalizations, 157 emergency visits, 660 outpatient consultations, and 155 related deaths, with 1,012 additional QALYs and 1,403 life-years gained. Savings from healthcare costs were USD 27.47 million, and the total amount, including vaccine costs, was USD 3.19 million, resulting in an ICER of 3,519 per QALY gained. The strategy was cost-effective under the WTP threshold. Sensitivity analyses highlight the impact of vaccine cost and RSV hospitalization incidence.
CONCLUSIONS: RSV vaccination is a cost-saving intervention that improves health outcomes in Colombian adults 60 years and older. Its inclusion in national immunization programs should be strongly considered to reduce the burden of RSV in aging populations.
METHODS: A decision-tree model simulated a fixed cohort of Colombian adults aged ≥60 over their remaining lifetime. The intervention was a one-time administration of a recombinant RSV prefusion F protein vaccine, compared with no vaccination. Epidemiological inputs were derived from Colombian and Latin American studies, in which administrative incidence data were used. General population mortality was obtained from the official life tables published by the National Financial Supervisory Authority. Costs were derived from expert consensus, official national reimbursement data, and PAHO records. Vaccine efficacy was obtained from the RENOIR randomized controlled trial, whereas vaccine effectiveness for hospitalization was from the Kaiser Permanente Southern California (KPSC) Study. A vaccine uptake of 17.8% is set, based on Influenza uptake for Colombian adults in 2018. A 5% annual discount rate was applied to both costs and outcomes. Deterministic and probabilistic sensitivity analyses were implemented to explore uncertainty. The willingness-to-pay (WTP) threshold was USD 8,266 per QALY gained
RESULTS: Vaccination averted 2,716 RSV-related hospitalizations, 157 emergency visits, 660 outpatient consultations, and 155 related deaths, with 1,012 additional QALYs and 1,403 life-years gained. Savings from healthcare costs were USD 27.47 million, and the total amount, including vaccine costs, was USD 3.19 million, resulting in an ICER of 3,519 per QALY gained. The strategy was cost-effective under the WTP threshold. Sensitivity analyses highlight the impact of vaccine cost and RSV hospitalization incidence.
CONCLUSIONS: RSV vaccination is a cost-saving intervention that improves health outcomes in Colombian adults 60 years and older. Its inclusion in national immunization programs should be strongly considered to reduce the burden of RSV in aging populations.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE302
Topic
Economic Evaluation
Disease
SDC: Geriatrics, STA: Vaccines